The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | CAR T-cell therapy in vitreoretinal lymphoma: challenges and upcoming trials in this space
Sylvain Choquet, MD, APHP, Paris, France, briefly discusses unanswered questions regarding the use of CAR T-cell therapy in patients with vitreoretinal lymphoma, a rare subtype of central nervous system (CNS) lymphoma. He highlights upcoming clinical trials in this space. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we have a huge experience with CAR T-cells in CNS lymphoma and vitreoretinal lymphoma, but we still have some unresolved questions in this field. The first one is in second-line, in patients who have not already had autologous stem cell transplant, is there a benefit to use CAR T-cells or to keep the reference which is stem cell transplant. So we are building a new study comparing these two options in second-line...
So we have a huge experience with CAR T-cells in CNS lymphoma and vitreoretinal lymphoma, but we still have some unresolved questions in this field. The first one is in second-line, in patients who have not already had autologous stem cell transplant, is there a benefit to use CAR T-cells or to keep the reference which is stem cell transplant. So we are building a new study comparing these two options in second-line. And the last question is in first line, normally the reference is autologous stem cell transplant, but some patients are too old and too fragile to have these treatments. So we also ask a question, is it possible for these patients to use CAR T-cells in first line? We will soon be at the end of the year, beginning of a new study with this question.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
